Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome.

BACKGROUND Some Escherichia coli produce Shiga toxin (Stx) in which cytotoxicity is increased (activated) by intestinal mucus and elastase (Stx2d(activatable)). These strains are highly virulent in mice, but their association with human disease is poorly understood. We investigated the prevalence of Stx2d(activatable) among Stx-producing E. coli (STEC) isolated from humans and the association between production of this Stx and the clinical outcome of infection. METHODS A total of 922 STEC isolates obtained from patients with hemolytic uremic syndrome or bloody or nonbloody diarrhea or from asymptomatic carriers were tested for the gene encoding Stx2d(activatable) by PCR and PstI restriction analysis. The toxin activatibility by human and mouse intestinal mucus and by an elastase was determined by quantifying the cytotoxicity using the Vero cell assay. RESULTS The stx(2d-activatable) gene was identified in 60 (6.5%) of 922 STEC strains; in 31 of these strains, it was the sole stx gene. Thirty of these 31 strains produced Stx2d(activatable). All of them lacked the intimin-encoding eae gene. Among eae-negative STEC, which typically cause mild diarrhea or asymptomatic infection, production of Stx2d(activatable) was significantly associated with the ability to cause severe disease, including bloody diarrhea (P<.001), and with systemic complications, such as hemolytic uremic syndrome (P<.001). CONCLUSIONS Production of Stx2d(activatable) by the infecting STEC may predict a severe clinical outcome of the infection, with progression to hemolytic uremic syndrome. A prompt and comprehensive subtyping of stx genes in STEC isolates is necessary to alert the treating physician that a patient is at risk of developing hemolytic uremic syndrome, even though the infecting STEC lacks eae.

[1]  L. Teel,et al.  A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Mellmann,et al.  Shiga Toxin 2e-Producing Escherichia coli Isolates from Humans and Pigs Differ in Their Virulence Profiles and Interactions with Intestinal Epithelial Cells , 2005, Applied and Environmental Microbiology.

[3]  J. Wells,et al.  Non-O157 Shiga toxin-producing Escherichia coli infections in the United States, 1983-2002. , 2005, The Journal of infectious diseases.

[4]  H. Karch,et al.  Enterohaemorrhagic Escherichia coli in human medicine. , 2005, International journal of medical microbiology : IJMM.

[5]  A. Mellmann,et al.  Enterohemorrhagic Escherichia coli in human infection: in vivo evolution of a bacterial pathogen. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  H. Karch,et al.  Molecular Profiling and Phenotype Analysis of Escherichia coli O26:H11 and O26:NM: Secular and Geographic Consistency of Enterohemorrhagic and Enteropathogenic Isolates , 2005, Journal of Clinical Microbiology.

[7]  H. Karch,et al.  Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium , 2005, Thrombosis and Haemostasis.

[8]  M. Ciol,et al.  Relative Nephroprotection During Escherichia coli O157:H7 Infections: Association With Intravenous Volume Expansion , 2005, Pediatrics.

[9]  H. Tschäpe,et al.  Diversity of virulence patterns among shiga toxin-producing Escherichia coli from human clinical cases-need for more detailed diagnostics. , 2005, International journal of medical microbiology : IJMM.

[10]  P. Tarr,et al.  Shiga-toxin-producing and haemolytic uraemic syndrome , 2005 .

[11]  S. Shankaran,et al.  Adverse Neurodevelopmental Outcomes Among Extremely Low Birth Weight Infants With a Normal Head Ultrasound: Prevalence and Antecedents , 2005, Pediatrics.

[12]  A. Friedrich,et al.  Transcriptional Analysis of Genes Encoding Shiga Toxin 2 and Its Variants in Escherichia coli , 2005, Applied and Environmental Microbiology.

[13]  A. Friedrich,et al.  A rapid method for the discrimination of genes encoding classical Shiga toxin (Stx) 1 and its variants, Stx1c and Stx1d, in Escherichia coli. , 2004, Molecular nutrition & food research.

[14]  A. Mellmann,et al.  Phylogeny, Clinical Associations, and Diagnostic Utility of the Pilin Subunit Gene (sfpA) of Sorbitol-Fermenting, Enterohemorrhagic Escherichia coli O157:H− , 2004, Journal of Clinical Microbiology.

[15]  C. Thorpe.  Shiga toxin-producing Escherichia coli infection. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  L. Beutin,et al.  Characterization of Shiga Toxin-Producing Escherichia coli Strains Isolated from Human Patients in Germany over a 3-Year Period , 2004, Journal of Clinical Microbiology.

[17]  H. Karch,et al.  Phenotypic and Genotypic Analyses of Enterohemorrhagic Escherichia coli O145 Strains from Patients in Germany , 2004, Journal of Clinical Microbiology.

[18]  A. Garg,et al.  Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. , 2003, JAMA.

[19]  R. Siegler.  Postdiarrheal Shiga toxin-mediated hemolytic uremic syndrome. , 2003, JAMA.

[20]  Gilbert S Chen,et al.  Shiga toxin-producing Escherichia coli in Montana: bacterial genotypes and clinical profiles. , 2003, The Journal of infectious diseases.

[21]  A. Fruth,et al.  Subtyping of pathogenic Escherichia coli strains using flagellar (H)-antigens: serotyping versus fliC polymorphisms. , 2003, International journal of medical microbiology : IJMM.

[22]  H. Karch,et al.  Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. , 2002, The Journal of infectious diseases.

[23]  H. Karch,et al.  Identification, Characterization, and Distribution of a Shiga Toxin 1 Gene Variant (stx1c) in Escherichia coli Strains Isolated from Humans , 2002, Journal of Clinical Microbiology.

[24]  A. O’Brien,et al.  Activation of Shiga toxin type 2d (Stx2d) by elastase involves cleavage of the C‐terminal two amino acids of the A2 peptide in the context of the appropriate B pentamer , 2002, Molecular microbiology.

[25]  A. Friedrich,et al.  Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. , 2002, The Journal of infectious diseases.

[26]  E. Elliott,et al.  Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features , 2001, Archives of disease in childhood.

[27]  J. H. Green,et al.  The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. , 2001, The Journal of infectious diseases.

[28]  Craig S. Wong,et al.  The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. , 2000, The New England journal of medicine.

[29]  A. Caprioli,et al.  A New Shiga Toxin 2 Variant (Stx2f) fromEscherichia coli Isolated from Pigeons , 2000, Applied and Environmental Microbiology.

[30]  A. O’Brien,et al.  Elastase in Intestinal Mucus Enhances the Cytotoxicity of Shiga Toxin Type 2d* , 2000, The Journal of Biological Chemistry.

[31]  J. Lanser,et al.  Molecular Characterization of a Shiga ToxigenicEscherichia coli O113:H21 Strain Lacking eaeResponsible for a Cluster of Cases of Hemolytic-Uremic Syndrome , 1999, Journal of Clinical Microbiology.

[32]  S. McEwen,et al.  Associations between Virulence Factors of Shiga Toxin-ProducingEscherichia coli and Disease in Humans , 1999, Journal of Clinical Microbiology.

[33]  S. Lauwers,et al.  Identification of New Verocytotoxin Type 2 Variant B-Subunit Genes in Human and Animal Escherichia coliIsolates , 1998, Journal of Clinical Microbiology.

[34]  A. O’Brien,et al.  Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice , 1996, Infection and immunity.

[35]  Serotype O104H.  Outbreak of acute gastroenteritis attributable to Escherichia coli serotype O104:H21--Helena, Montana, 1994. , 1995, MMWR. Morbidity and mortality weekly report.

[36]  A. Melton,et al.  Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model , 1993, Infection and immunity.

[37]  M. McKee,et al.  The role of the eae gene of enterohemorrhagic Escherichia coli in intimate attachment in vitro and in a porcine model. , 1993, The Journal of clinical investigation.

[38]  M. P. Jackson,et al.  Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. , 1992, Current topics in microbiology and immunology.

[39]  M. McKee,et al.  Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511 , 1991, Infection and immunity.

[40]  Y. Takeda,et al.  Cloning and nucleotide sequencing of Vero toxin 2 variant genes from Escherichia coli O91:H21 isolated from a patient with the hemolytic uremic syndrome. , 1990, Microbial pathogenesis.

[41]  H. Lior,et al.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. , 1985, The Journal of infectious diseases.